Patents Assigned to Immutep S.A.
-
Publication number: 20230330182Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: May 5, 2023Publication date: October 19, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20230272107Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation.Type: ApplicationFiled: May 5, 2023Publication date: August 31, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20230210946Abstract: This invention relates to the use of a LAG-3 protein or a derivative thereof and optionally a chemotherapy agent for the treatment of cancer in a subject. The subject may have one or more of a low monocyte count, a Luminal B breast cancer, an age of less than about 85 years, has been previously treated with a CDK4/6 inhibitor, and has not previously undergone treatment with a taxane chemotherapy. Suitably, the cancer is a breast cancer, such as a hormone receptor positive breast cancer.Type: ApplicationFiled: March 24, 2021Publication date: July 6, 2023Applicant: Immutep S.A.S.Inventor: Frederic TRIEBEL
-
Patent number: 11684654Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: October 16, 2020Date of Patent: June 27, 2023Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Patent number: 11680104Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4+ and/or CD8+ T cells, such as inflammatory and autoimmune disorders.Type: GrantFiled: September 1, 2016Date of Patent: June 20, 2023Assignee: IMMUTEP S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone
-
Publication number: 20230074746Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells).Type: ApplicationFiled: September 6, 2022Publication date: March 9, 2023Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20210177937Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: October 16, 2020Publication date: June 17, 2021Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Patent number: 10940181Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: January 3, 2020Date of Patent: March 9, 2021Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Patent number: 10874713Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: GrantFiled: January 8, 2016Date of Patent: December 29, 2020Assignee: IMMUTEP S.A.S.Inventors: Frederic Triebel, Chrystelle Brignone
-
Publication number: 20200323957Abstract: Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.Type: ApplicationFiled: July 1, 2020Publication date: October 15, 2020Applicant: IMMUTEP S.A.S.Inventor: Frederic Triebel
-
Patent number: 10736940Abstract: Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.Type: GrantFiled: December 19, 2014Date of Patent: August 11, 2020Assignee: IMMUTEP S.A.S.Inventor: Frederic Triebel
-
Patent number: 10711060Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: GrantFiled: December 1, 2017Date of Patent: July 14, 2020Assignees: NOVARTIS AG, Immutep S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Publication number: 20200121757Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.Type: ApplicationFiled: January 3, 2020Publication date: April 23, 2020Applicant: IMMUTEP S.A.S.Inventors: Frederic TRIEBEL, Chrystelle BRIGNONE
-
Publication number: 20180340025Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: ApplicationFiled: July 28, 2016Publication date: November 29, 2018Applicants: Novartis AG, Immutep S.A.S.Inventors: Glenn Dranoff, Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 9908936Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.Type: GrantFiled: March 24, 2017Date of Patent: March 6, 2018Assignees: Novartis AG, Immutep S.A.S.Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
-
Patent number: 8425897Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: GrantFiled: August 29, 2008Date of Patent: April 23, 2013Assignee: Immutep S.A.Inventors: Karin Jooss, Betty Li, Frederic Triebel
-
Publication number: 20090130054Abstract: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: August 29, 2008Publication date: May 21, 2009Applicants: Cell Genesys, Inc., Immutep S.A.Inventors: Karin Jooss, Betty Li, Frederic Triebel